Related Experiment Video
Updated: Apr 24, 2026
Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
Published on: April 17, 2021
Effect of spironolactone on cardiac remodeling after acute myocardial infarction
Chun-Tao Wu1, Zhong-Hua Wang2, Zhu-Qin Li2
1Department of Cardiology, Second Affiliated Hospital, Qiqihar Medical College, Qiqihar 161006, China.
Insights
Low-dose spironolactone (ARA) effectively inhibits cardiac remodeling and prevents heart failure after acute myocardial infarction (AMI). This study shows significant improvements in cardiac function and structure with ARA treatment.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Limited research exists on aldosterone receptor antagonists (ARAs) and myocardial remodeling post-acute myocardial infarction (AMI).
- This study aimed to evaluate the preventive effects of ARAs on cardiac remodeling following AMI.
Purpose of the Study:
- To investigate the efficacy of spironolactone, an ARA, in preventing cardiac remodeling after AMI.
- To assess the impact of spironolactone on left ventricular function, renal function, and electrolyte balance.
Main Methods:
- Prospective study of 528 patients post-AMI, divided into control and spironolactone treatment groups.
- Echocardiography, serum potassium, and serum creatinine levels were monitored at one-month and one-year follow-up.
Main Results:
- Spironolactone treatment significantly improved echocardiographic indicators of cardiac remodeling (LVESD, LVEDD, LVEF, LAD-ML, LAD-SI) at one year compared to the control group.
- Treatment group showed greater improvements in cardiac remodeling markers from one month to one year than the control group.
- No significant differences in serum potassium or creatinine levels were observed between groups.
Conclusions:
- Early combination therapy with low-dose spironolactone (20 mg/d) alongside conventional treatment inhibits late-stage cardiac remodeling.
- Spironolactone demonstrates potential in preventing heart failure development after AMI.
Background:
Few studies have reported the effect of aldosterone receptor antagonist (ARA) on myocardial remodeling after acute myocardial infarction (AMI). This study was undertaken to investigate the preventive effect of ARA on myocardial remodeling after AMI.
Methods:
A total of 616 patients who had been admitted into the CCU of the First Affiliated Hospital of Harbin Medical University from January 2008 to January 2010 were studied prospectively. Only 528 patients were observed completely, including 266 of the control group and 262 of the treatment group. There was no statistical difference in age, gender, medical history, admission situation, and treatment between the two groups (P>0.05). The preventive effects of spironolactone on cardiac remodeling, left ventricular function, renal function and blood levels of potassium were evaluated by echocardiography, serum potassium and serum creatinine at one-month and one-year follow-up.
Results:
The echocardiography indicators such as LVESD, LVEDD, LVEF, LAD-ML and LAD-SI were significantly improved in the treatment group compared with the control group at one year (P<0.05). In the treatment group, LVESD, LVEDD, LVPWT, LVEF, LAD-ML and LAD-SI were more significantly improved at one year than one month (P<0.05, P=0.007 to LVEF), and in the control group LVEF was more significantly improved at one year than one month (P=0.0277). There were no significant differences in serum potassium and serum creatinine levels between the two groups.
Conclusion:
On the basis of conventional treatment, the early combination of low-dose spironolactone (20 mg/d) could inhibit cardiac remodeling at late stage and prevent heart failure.
More Related Videos
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
09:37Permanent Ligation of the Left Anterior Descending Coronary Artery in Mice: A Model of Post-myocardial Infarction Remodelling and Heart Failure
Published on: December 2, 2014
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:28Acute Coronary Syndrome IV: Interprofessional Care
01:14Myocarditis III: Medical Management
01:22Heart Failure Drugs: Diuretics